Sensorion SA (ALSEN) - Total Liabilities

Latest as of December 2025: €13.41 Million EUR ≈ $15.68 Million USD

Based on the latest financial reports, Sensorion SA (ALSEN) has total liabilities worth €13.41 Million EUR (≈ $15.68 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ALSEN long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Sensorion SA - Total Liabilities Trend (2011–2025)

This chart illustrates how Sensorion SA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Sensorion SA (ALSEN) total assets.

Sensorion SA Competitors by Total Liabilities

The table below lists competitors of Sensorion SA ranked by their total liabilities.

Company Country Total Liabilities
Creades AB Series A
LSE:0QI9
UK Skr39.00 Million
JUTAL OFF.OIL SRVCS HD-01
F:I8O
Germany €788.06 Million
Inspired Entertainment Inc
NASDAQ:INSE
USA $408.50 Million
Triple i Logistics Public Company Limited
BK:III
Thailand ฿1.01 Billion
Chongkundang
KO:001630
Korea ₩755.22 Billion
Dat Phuong JSC
VN:DPG
Vietnam ₫6.04 Trillion
Adriano Care SOCIMI SAU
MC:YADR
Spain €132.09 Million
Sat Nusapersada Tbk
JK:PTSN
Indonesia Rp125.64 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Sensorion SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Sensorion SA net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.59 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 2.24 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.30 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.23 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sensorion SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sensorion SA (2011–2025)

The table below shows the annual total liabilities of Sensorion SA from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 €13.41 Million
≈ $15.68 Million
-21.77%
2024-12-31 €17.14 Million
≈ $20.04 Million
+29.57%
2023-12-31 €13.23 Million
≈ $15.46 Million
-22.47%
2022-12-31 €17.06 Million
≈ $19.94 Million
+13.47%
2021-12-31 €15.03 Million
≈ $17.58 Million
+57.85%
2020-12-31 €9.52 Million
≈ $11.13 Million
-61.72%
2019-12-31 €24.88 Million
≈ $29.09 Million
+317.68%
2018-12-31 €5.96 Million
≈ $6.96 Million
+55.06%
2017-12-31 €3.84 Million
≈ $4.49 Million
+17.86%
2016-12-31 €3.26 Million
≈ $3.81 Million
-11.91%
2015-12-31 €3.70 Million
≈ $4.33 Million
+47.11%
2014-12-31 €2.52 Million
≈ $2.94 Million
+7.83%
2013-12-31 €2.33 Million
≈ $2.73 Million
+561.52%
2012-12-31 €352.61K
≈ $412.24K
+67.50%
2011-12-31 €210.51K
≈ $246.11K
--

About Sensorion SA

PA:ALSEN France Biotechnology
Market Cap
$5.53 Billion
€4.73 Billion EUR
Market Cap Rank
#18527 Global
#268 in France
Share Price
€9.19
Change (1 day)
-2.29%
52-Week Range
€0.22 - €10.47
All Time High
€12.53
About

Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutat… Read more